Clinical Utility of Pharmacy-Based Adherence Measurement in Predicting Virologic Outcomes in an Adult HIV-Infected Cohort in Jos, North Central Nigeria
Isaac Okoh Abah, Victor Bazim Ojeh, Jonah Musa, Placid Ugoagwu, Patricia Aladi Agaba, Oche Agbaji and Prosper Okonkwo
Journal of the International Association of Providers of AIDS Care (JIAPAC) published online 24 June 2014
DOI: 10.1177/2325957414539197

The online version of this article can be found at:
http://jia.sagepub.com/content/early/2014/06/24/2325957414539197

Published by:
SAGE
http://www.sagepublications.com

On behalf of:
IATAC
International Association of Physicians in AIDS Care

Additional services and information for Journal of the International Association of Providers of AIDS Care (JIAPAC) can be found at:

Email Alerts: http://jia.sagepub.com/cgi/alerts

Subscriptions: http://jia.sagepub.com/subscriptions

Reprints: http://www.sagepub.com/journalsReprints.nav

Permissions: http://www.sagepub.com/journalsPermissions.nav

>> OnlineFirst Version of Record - Jun 24, 2014

What is This?
Clinical Utility of Pharmacy-Based Adherence Measurement in Predicting Virologic Outcomes in an Adult HIV-Infected Cohort in Jos, North Central Nigeria

Isaac Okoh Abah, BPharm, MSc¹, Victor Bazim Ojeh, BPharm¹, Jonah Musa, MBBS, MSCI², Placid Ugoagwu, BSc¹, Patricia Aladi Agaba, MBBS², Oche Agbaji, MBBS², and Prosper Okonkwo, MBBS³

Abstract
Objectives: We examined the association between adherence to drug-refill visits and virologic outcomes in a cohort of HIV-infected adults on combination antiretroviral therapy (cART) in North Central Nigeria. Methods: Retrospectively, 588 HIV-infected, cART-naive adults (aged ≥15 years), initiated on first-line ART between 2009 and 2010 at the Jos University Teaching Hospital, were evaluated. Association between adherence to drug-refill visits, virologic (viral load > 1000 copies/mL), and immunologic failure was assessed using multivariable logistic regression. Results: After a median of 12 months on cART, 16% (n = 94) and 10% (n = 59) of patients had virologic and immunologic failures, respectively. In the final multivariable model, suboptimal adherence to drug-refill visits was a significant predictor of both virologic (adjusted odds ratio [AOR] 1.6; 95% confidence interval [CI]:1.2–2.3) and immunologic (AOR 1.92; 95% CI:1.06–3.49) failures. Conclusion: Adherence to drug refill is a useful predictor of successful virologic control and could be utilized for routine monitoring of adherence to cART in our clinical setting.

Keywords
pharmacy, drug refill, adherence, HIV, virologic outcome

Introduction
Sub-Saharan Africa (SSA) has witnessed a sustained reduction in AIDS-related mortality as a result of increased access to lifesaving antiretroviral therapy (ART). The number of people dying of AIDS-related causes was cut by 32% between 2005 and 2011.¹ Antiretroviral therapy also significantly reduced the risk of HIV transmission² and the spread of tuberculosis.³ Nigeria ranks second in the global burden of HIV (next to South Africa), having an estimated 3.5 million people living with HIV and AIDS.⁴ Expansion of HIV treatment services in Nigeria started in 2004 with the support of the US President’s Emergency Plan for AIDS Relief (PEPFAR) program. This resulted in more than 3-fold increases in the number of people accessing antiretroviral (ARV) medications from 108572 to 395569, between 2006 and 2011.⁵

Despite historic gains in the expansion of treatment services, adherence to combination ART (cART) remains a significant challenge to sustaining the benefits of ART. Suboptimal adherence results in virological failure,⁶⁻⁹ development of HIV drug resistance,¹⁰⁻¹² and death.¹³ One study showed that, for every 10% decrease in adherence, there is a 16% increase in HIV-related mortality.⁷ In another study, there was 28% reduction in the risk of progression to AIDS with each 10% difference in mean adherence.⁸ Early identification of patients at risk of poor treatment outcomes through accurate and continuous assessment of adherence is important for effective and efficient treatment planning. This will also inform the provision of targeted adherence support.

Pharmacy refill data could serve as an adherence measure by providing the dates on which ARV medications were dispensed. It is a less intrusive method of measuring adherence than most other measures. A number of studies on the treatment of HIV and other diseases have used pharmacy refill records to

1 Jos University Teaching Hospital, AIDS Prevention Initiative in Nigeria (APIN), Jos, Nigeria
2 University of Jos/Jos University Teaching Hospital, APIN Centre, Jos, Nigeria
3 AIDS Prevention Initiative in Nigeria Ltd, Abuja, Nigeria

Corresponding Author:
Abah O. Isaac, Jos University Teaching Hospital, AIDS Prevention Initiative in Nigeria, Jos, Nigeria.
Email: isaacabah@gmail.com
assess adherence.\textsuperscript{14,15} In a study, patients with regular pharmacy refills for $\geq$4 months were more likely than less adherent patients to achieve virologic suppression and immunologic improvement.\textsuperscript{16} In another study, a cumulative adherence of $<95\%$ to drug-refill visits was associated with virologic and immunologic failure and was comparable to CD4 counts for detecting current virologic failure in the cohort of patients on cART.\textsuperscript{17}

Although Nigeria contributes significantly to the global HIV burden,\textsuperscript{4} very little is known about the virologic outcome of pharmacy refill adherence in public care facilities in Nigeria due to poor availability of viral load (VL) testing. Lack of emphasis on VL testing in ART programs in SSA is related to financial and technical constraints and the public health model adopted for the management of HIV in Africa.\textsuperscript{18,19} The current study is aimed at evaluating the impact of adherence to drug-refill schedules on immunological and virological outcomes in a cohort of adult Nigerian patients on cART.

\section*{Methods}

\section*{Setting and Study Population}

Jos University Teaching hospital (JUTH) is located in North Central Nigeria. JUTH HIV clinic is an outpatient clinic and is one of the largest providers of treatment, care, and support to people living with HIV in Nigeria. At the time of study, over 13 000 adults were enrolled in care and approximately 9300 patients were on treatment. Since 2004, the JUTH HIV clinic has received additional funding and support from the US PEPFAR program through the Harvard School of Public Health.

\section*{Eligibility Criteria}

HIV-1-infected (confirmed positive by Western blot) treatment-naive adults (15 years and older) started on first-line ART between January 2009 and December 2010 and followed up through December 2011 were included in a retrospective cohort analysis. Antiretroviral therapy eligibility criteria were based on the Nigerian National guidelines for HIV/AIDS treatment and care in adolescents and adults,\textsuperscript{20} which at the time of the study recommended ART for those with a CD4 count $<200$ cells/mm$^3$ regardless of the symptom or with CD4 count $<350$ cells/mm$^3$ with HIV-related symptoms.

\section*{Standard of Care}

Antiretroviral therapy-eligible patients were initiated on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based cART defined as an NNRTI plus 2 nucleoside reverse transcriptase inhibitors (NRTIs), a criterion chosen based on the Nigerian National Adult ART Guidelines and its significance to resource-limited settings (RLSs).\textsuperscript{21,22} At ART initiation, patient’s received information on ART and the importance of adherence. Patients were dispensed ART monthly and at scheduled doctor visits. They were also given projected monthly pharmacy refill dates and the date for the next appointment with the doctor. At each refill visit, a pharmacist dispensed ARV pills and entered the dispense data into an electronic pharmacy record (FileMaker Pro, v10, Santa Clara, California), which had been developed as part of the Harvard PEPFAR/APIN Plus program. All the patients had HIV-1 VL (Amplicor HIV-1 Monitor v1.5, Roche Diagnostics, GmbH, Mannheim, Germany, lower detection limit 400 copies/mL) and CD4 count (CyFlow, Partec, Munster, Germany) pre-ART initiation, at 12 weeks, and subsequently every 24 weeks per clinical care protocols.

\section*{Data Collection and Ethical Consideration}

Data retrieved for analysis from the Harvard PEPFAR/APIN Plus program database included baseline sociodemographic data (age, gender, occupation, and marital status), clinical characteristics pre-ART initiation, drug pickup history (date, number of pills dispensed, and regimen), CD4 count, and VL results pre-ART, at 24, and 48 weeks. The clinical protocols and use of data for studies have been approved by JUTH ethics committee, and all enrolled patients provided informed consent for the use of their data for research.

\section*{Outcome Definition}

Virologic failure was defined as plasma VL above 1000 copies/mL based on 2 consecutive VL measurements after 6 to 12 months of cART initiation. Lack of responses within the first year was chosen as an outcome because of the clinical importance of initial response to cART on subsequent disease outcomes.\textsuperscript{23} Immunological failure was defined as having a CD4 count of equal to or less than CD4 count pre-ART, after 6 months on ART, or a CD4 count of 100 cells/mm$^3$ past 6 months on ART.\textsuperscript{24} Drug refill adherence was calculated automatically by the computerized pharmacy appointment system using the total number of days that the patient was behind for the drug-refill visits, based on the following formula:

\[ \text{Percentage of cumulative adherence} = \frac{\text{number of days behind for drug-refill visit}}{\text{total number of days behind schedule/total number of days}} \times 100. \]

The results were then added up for all refill visits to obtain the total number of days behind the scheduled visit per patient. Percentage of cumulative adherence was estimated by the following formula:

\[ \text{Optimal and suboptimal adherence} = \frac{\text{total number of days behind schedule/total number of days the patient was assumed to be exposed to ART given the dispensed number of pills}}{100}. \]

Optimal and suboptimal adherence was defined as a cumulative adherence to drug-refill visits of $\geq 95\%$ and $<95\%$, respectively.

\section*{Statistical Analysis}

Continuous variables were described by means and standard deviation (SD) or median and interquartile range (IQR) as appropriate based on the distribution, while categorical variables were described by frequencies and proportions. Bivariate
analyses to evaluate factors associated with virologic and immunologic failure were performed using Pearson chi-square test. Thereafter, variables with a *P* value < .1 were included in a multivariate logistic regression model. In the final multivariable model, sex, age and ARV regimen were maintained to account for any residual confounders. Odds ratios (ORs), 95% confidence intervals (CIs), and *P* values were determined, with *P* values < .05 considered significant. All *P* values were 2 tailed. Data were analyzed with SPSS for windows version 20 (SPSS Inc, Chicago, Illinois).

**Results**

Patient’s disposition and primary outcomes are shown in Figure 1. A total of 1274 adults were initiated on NNRTI-based cART. Of the 1274 participants, 588 (46%) had sufficient CD4 count and VL data both at baseline and at follow-up to be included in the primary outcome analysis. The median age of the patients included in the analysis was 34 years (interquartile range [IQR] 29–41 years). There were more females (65%) than males and most (53.7%) of the participants were married (Table 1). Median duration on ART was 12 months (IQR 6–12) at study end point. Baseline median (IQR) CD4 count and VL were similar among patients with insufficient follow-up data and those with sufficient follow-up data; (163 [88–264] vs 167 [91–167] cells/mm³ [*P* = .5] and 4.5 [3.7–5.2] vs 4.6 [4–5.2] log₁₀ copies/mL [*P* = .6], respectively).

**Adherence Characteristics**

The mean cumulative percentage adherence to drug-refill visits was 94% (95% CI: 94-95). Overall, 250 (42.5%) patients had suboptimal adherence (<95%). In a separate analysis,
sociodemographic characteristics were not significantly associated with adherence to drug pickup (Table 1).

Virologic Failure

In all, 94 (16%) of the 588 patients had virologic failure. Median interval of repeat VL test was 6 months (IQR 5–7). Variables associated with virologic failure (Table 2) in the bivariate analysis included sex, age, drug pickup adherence, pre-ART CD4 count, and pre-ART VL. After adjusting for other confounders (Table 3), suboptimal adherence to drug-refill visits was the only significant predictor of virologic failure (adjusted OR [AOR] 1.61; 95% CI: 1.15–2.27).

Immunological Failure

A total of 59 (10%) of 588 met the criteria for immunological failure. In the bivariate analysis, factors associated with immunological failure included NRTI backbone (P = .01), pre-ART CD4 count (P < .001), pre-ART VL (P = .05), and WHO disease stage at ART initiation (P = .02). In the final multivariable logistic regression model, risk factors for immunologic failure were a cumulative adherence to drug refill <95% (AOR 1.92; 95% CI: 1.15–3.49) and pre-ART CD4 count ≤100 cells/mm³ (AOR 7.71; 95% CI: 4.02–14.80).

Discussion

This study provides evidence for the usefulness of pharmacy-refill adherence measure in predicting virologic outcomes among patients on cART in a public care facility in Nigeria. Using 2 VL measurements during the first year of treatment, drug-refill adherence was significantly associated with virologic failure in our study participants. Patients with optimal adherence (>95%) to drug-refill schedules had a better likelihood of achieving maximal viral suppression within the first year of treatment. Clinically, this is useful as systematic monitoring of adherence using validated methods should be part of standard clinical procedures. This will help to identify patients with suboptimal adherence and enhance the provision of targeted adherence interventions.

Unlike other investigators,17,26,28,29 we observed rates of viral suppression that were higher than drug pickup adherence. Although pharmacy-refill adherence has been shown to
correlate with virologic response and mortality in developed and RLSs,\textsuperscript{17,28,29} it gives no description of daily adherence to treatment and is limited in describing patient’s pill-taking behavior. Other investigators have noted discordance between adherence determined using pharmacy records and virologic response.\textsuperscript{30} Furthermore, other studies have indicated that moderate adherence levels (70–90\%) may be enough to achieve satisfactory virologic control with ARV regimens including boosted protease inhibitors or NNRTIs.\textsuperscript{31} However, at the 95\% adherence level, we can be quite confident that a

Table 2. Demographic and Clinical Characteristics and Bivariate Analysis for the Association with Immunologic and Virologic Failure among 588 Patients on ART in Jos, Nigeria.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Group</th>
<th>Immunologic Failure, n = 59 (10%)</th>
<th>P Value</th>
<th>Virologic Failure, n = 94 (16%)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Female</td>
<td>37 of 392 (9.4%)</td>
<td>.51</td>
<td>72 of 392 (18.4%)</td>
<td>.03\textsuperscript{a}</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>22 of 196 (11.2%)</td>
<td></td>
<td>22 of 196 (11.2%)</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>≤35</td>
<td>34 of 332 (10.2%)</td>
<td>.85</td>
<td>62 of 332 (18.7%)</td>
<td>.04\textsuperscript{a}</td>
</tr>
<tr>
<td></td>
<td>&gt;35</td>
<td>25 of 356 (9.8%)</td>
<td></td>
<td>32 of 256 (12.5%)</td>
<td></td>
</tr>
<tr>
<td>WHO disease stage</td>
<td>1</td>
<td>11 of 216 (5.1%)</td>
<td>.02\textsuperscript{a}</td>
<td>25 of 216 (11.6%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>10 of 102 (9.8%)</td>
<td></td>
<td>20 of 102 (19.6%)</td>
<td>.15</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>31 of 233 (13.3%)</td>
<td></td>
<td>42 of 233 (18%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>5 of 29 (17.2%)</td>
<td></td>
<td>6 of 29 (20.7%)</td>
<td></td>
</tr>
<tr>
<td>NNRTI</td>
<td>EFV</td>
<td>25 of 188 (13.3%)</td>
<td>.71</td>
<td>28 of 188 (14.9%)</td>
<td>.62</td>
</tr>
<tr>
<td></td>
<td>NVP</td>
<td>34 of 400 (8.5%)</td>
<td></td>
<td>66 of 400 (16.5%)</td>
<td></td>
</tr>
<tr>
<td>NRTI</td>
<td>ZDV</td>
<td>14 of 234 (6%)</td>
<td>.01\textsuperscript{a}</td>
<td>31 of 234 (13.2%)</td>
<td>.09</td>
</tr>
<tr>
<td></td>
<td>TDF</td>
<td>45 of 354 (12.7%)</td>
<td></td>
<td>63 of 354 (17.8%)</td>
<td></td>
</tr>
<tr>
<td>Adherence</td>
<td>&lt;95</td>
<td>31 of 250 (12.4%)</td>
<td>.09</td>
<td>49 of 250 (19.6%)</td>
<td>.04\textsuperscript{a}</td>
</tr>
<tr>
<td></td>
<td>≥95</td>
<td>28 of 338 (8.3%)</td>
<td></td>
<td>45 of 338 (13.3%)</td>
<td></td>
</tr>
<tr>
<td>CD4 count, cells/mm\textsuperscript{3}</td>
<td>≤100</td>
<td>44 of 172 (25.6%)</td>
<td>&lt;.001\textsuperscript{a}</td>
<td>45 of 172 (26.2%)</td>
<td>&lt;.001\textsuperscript{a}</td>
</tr>
<tr>
<td></td>
<td>&gt;100</td>
<td>15 of 416 (3.6%)</td>
<td></td>
<td>49 of 416 (11.8%)</td>
<td></td>
</tr>
<tr>
<td>Viral Load, copies/mL</td>
<td>≤100 000</td>
<td>32 of 388 (8.2%)</td>
<td>.05</td>
<td>51 of 388 (13.1%)</td>
<td>.01\textsuperscript{a}</td>
</tr>
<tr>
<td></td>
<td>&gt;100 000</td>
<td>27 of 200 (13.5%)</td>
<td></td>
<td>43 of 200 (21.5%)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ART, antiretroviral therapy; 3TC, lamivudine; EFV, efavirenz; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NVP, nelfinavir; TDF, tenofovir; ZDV, zidovudine.

\textsuperscript{a}Significant.

Table 3. Adjusted Association Between Characteristics of Patient and Immunologic and Virologic Failure.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Group</th>
<th>Immunological Failure\textsuperscript{a}</th>
<th>P Value</th>
<th>Virological Failure\textsuperscript{b}</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Female</td>
<td>1.17 (0.59-2.30)</td>
<td>.64</td>
<td>1.06 (0.63-1.78)</td>
<td>.82</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>1</td>
<td></td>
<td>1.42 (0.99-2.03)</td>
<td>.05</td>
</tr>
<tr>
<td>Age</td>
<td>≤35</td>
<td>1.09 (0.59-2.07)</td>
<td>.76</td>
<td>0.81 (0.35-1.83)</td>
<td>.61</td>
</tr>
<tr>
<td></td>
<td>&gt;35</td>
<td>1</td>
<td></td>
<td>0.81 (0.34-1.92)</td>
<td>.62</td>
</tr>
<tr>
<td>WHO disease stage</td>
<td>1</td>
<td>0.58 (0.17-2.01)</td>
<td>.39</td>
<td>0.81 (0.34-1.92)</td>
<td>.62</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>0.96 (0.27-3.39)</td>
<td>.94</td>
<td>1.06 (0.48-2.35)</td>
<td>.88</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>0.95 (0.31-2.91)</td>
<td>.93</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>1</td>
<td></td>
<td></td>
<td>.53</td>
</tr>
<tr>
<td>NNRTI</td>
<td>Efavirenz</td>
<td>1.24 (0.50-3.09)</td>
<td>.63</td>
<td>1.28 (0.73-2.23)</td>
<td>.38</td>
</tr>
<tr>
<td></td>
<td>Nevirapine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRTI</td>
<td>Tenofovir</td>
<td>0.57 (0.28-1.21)</td>
<td>.14</td>
<td>0.70 (0.47-1.02)</td>
<td>.06</td>
</tr>
<tr>
<td></td>
<td>Zidovudine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adherence</td>
<td>&lt;95%</td>
<td>1.92 (1.06-3.49)</td>
<td>.03\textsuperscript{c}</td>
<td>1.61 (1.15-2.27)</td>
<td>&lt;.001\textsuperscript{c}</td>
</tr>
<tr>
<td></td>
<td>≥95%</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-ART CD4 count, cells/mm\textsuperscript{3}</td>
<td>≤100</td>
<td>7.71 (4.02-14.80)</td>
<td>&lt;.001\textsuperscript{c}</td>
<td>1.29 (0.88-1.91)</td>
<td>.19</td>
</tr>
<tr>
<td></td>
<td>&gt;100</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-ART viral load, copies/mL</td>
<td>≤100 000</td>
<td>0.73 (0.4-1.32)</td>
<td>.29</td>
<td>0.74 (0.52-1.07)</td>
<td>.11</td>
</tr>
<tr>
<td></td>
<td>&gt;100 000</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ART, antiretroviral therapy; AOR, adjusted odds ratio; CI, confidence interval; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; NVP, nelfinavir; TDF, tenofovir; ZDV, zidovudine.

\textsuperscript{a}As defined by WHO.

\textsuperscript{b}Two repeated VL > 1000 copies/mL.

\textsuperscript{c}Significant.
very small proportion of individuals on NNRTIs are likely to have virological failure. In addition, other measures of adherence, including subjective measures that were not evaluated in this study, ought to be examined as should correctness of this approach in patients on non-NNRTI-based cART.

Like other investigators, we found that, independent of adherence, patients initiating treatment at CD4 counts less than <100 cells/mm$^3$ have a higher risk of immunologic failure within the first year of treatment. The benefits of initiating treatment at higher CD4 thresholds have been described in other studies. The most recent treatment guidelines favor treatment initiation at higher CD4 count thresholds.

As a result of inconsistent VL data, a large proportion (54%) of participants were excluded from the primary outcome analysis due to our strict inclusion criteria; however, comparison of patients included and excluded did not show any clinically significant differences in the baseline CD4 counts, VLs, and adherence profile.

**Conclusion**

Virologic suppression within the first year of treatment with an NNRTI-based regimen was significant in our study population. Adherence measured by pharmacy drug refill could serve as a useful predictor of early virologic failure. We, therefore, recommend that it should be used in routine monitoring of adult HIV-infected patients on cART in RLS.

**Authors’ Note**

This article was presented at the 8th International Conference on HIV Treatment and Prevention Adherence, Miami, Florida, USA, on June 2013. Oral Abstract # 175. We thank Kimberly Scarci for her support in critically reviewing the manuscript. We also thank the patients and staff of the JUTH HIV clinic.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded in part by the US Department of Health and Human Services, Health Resources and Services Administration (US1HA02522) and CDC through APIN (PS 001058). The contents are solely the responsibility of the authors and do not represent the official views of the funding institutions.

**References**


